Vertex Pharmaceuticals price target raised to $450 from $433 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares.
Scotiabank raises Vertex stock price target to $450
Scotiabank (TSX:BNS) analyst Greg Harrison updated the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a ...
Morgan Stanley lifts Vertex stock price target to $459
Morgan Stanley (NYSE:MS) adjusted its outlook on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, raising the price target from the previous $450.00 to $459.00, while maintaining an ...